Clinical trial
An Open-label, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function.
NCT01429337 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function.
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 7, 2011
- Completion date
- May 9, 2020
- Enrollment
- 43 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
hepatic impairment